Literature DB >> 19625212

Detection of the protease codon 35 amino acid insertion in sequences from treatment-naïve HIV-1 subtype C infected individuals in the Central Region of Portugal.

João Pereira-Vaz1, Vitor Duque, Luís Trindade, José Saraiva-da-Cunha, António Meliço-Silvestre.   

Abstract

BACKGROUND: Amino acids insertions in the protease (PR) coding region have been reported in protease inhibitors (PIs) treatment-naïve and experienced HIV-1 infected individuals ranging from 0.1% to 4.55% and have been rarely found in non-B HIV-1 subtype strains.
OBJECTIVES: To investigate the presence of amino acid insertions in the PR coding region in sequences from treatment-naïve HIV-1 infected individuals in the Central Region of Portugal. STUDY
DESIGN: Sequences of the pol gene from 260 treatment-naïve HIV-1 infected individuals between 2000 and 2008 were analyzed and phylogenetic analysis was performed.
RESULTS: A threonine insertion (E35E_T) was detected in 2.69% (n=7) of the sequences analyzed and all the sequences that possessed this insertion were identified as subtype C. All the seven inserted sequences clustered in the same lineage of the phylogenetic tree. Heterosexual and intravenous drug use were found to be the routes of infection. No major mutations in the PR coding region associated with resistance to PIs were detected.
CONCLUSIONS: It was found the highest prevalence of PR codon 35 insertion among treatment-naïve HIV-1 infected individuals ever reported in the western countries. Epidemiological data and Phylogenetic analysis indicated the possibility of transmission of this insertion. The results suggested that these inserted strains have normal susceptibility to PIs containing regimens. This study demonstrated the spreading epidemic of PR codon 35 inserted strains from subtype C in the Central Region of Portugal, during the past eight years.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625212     DOI: 10.1016/j.jcv.2009.06.019

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  7 in total

Review 1.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

2.  GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.

Authors:  Klára Grantz Šašková; Milan Kozíšek; Kirsten Stray; Dorien de Jong; Pavlína Rezáová; Jirí Brynda; Noortje M van Maarseveen; Monique Nijhuis; Tomáš Cihlár; Jan Konvalinka
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

3.  HIV-1 Protease: Structural Perspectives on Drug Resistance.

Authors:  Irene T Weber; Johnson Agniswamy
Journal:  Viruses       Date:  2009-12-03       Impact factor: 5.048

4.  Primary HIV Drug Resistance among Recently Infected Cases of HIV in North-West India.

Authors:  C K Chauhan; P V M Lakshmi; V Sagar; A Sharma; S K Arora; R Kumar
Journal:  AIDS Res Treat       Date:  2019-02-27

5.  HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.

Authors:  Miaomiao Li; Shujia Liang; Chao Zhou; Min Chen; Shu Liang; Chunhua Liu; Zhongbao Zuo; Lei Liu; Yi Feng; Chang Song; Hui Xing; Yuhua Ruan; Yiming Shao; Lingjie Liao
Journal:  Pathogens       Date:  2021-02-25

6.  Frequency of resistance to first-line antiretroviral therapy observed among HIV patients.

Authors:  Feroz Khan; Muhammad Bilal; Muhammad Yaseen Khan; Mian Fareezuddin
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340

Review 7.  Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.

Authors:  Ruxandra-Cristina Marin; Tapan Behl; Nicoleta Negrut; Simona Bungau
Journal:  Biomedicines       Date:  2021-03-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.